本帖最后由 老马 于 2013-3-13 13:43 编辑
3 R5 v: P. ^- G5 k* G! O. P$ X2 e1 x! ~, q* n, r" c
健择（吉西他滨）+顺铂+阿瓦斯汀4 ^9 ^* w! C, i( h( S7 ?) y: V
Gemzar +Cisplatin + Avastin
3 R4 D- W( p: [/ I0 [' Ihttp://annonc.oxfordjournals.org/content/21/9/1804.full2 ?* h8 B* B& f' o& }; I1 K
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) / f. k4 q: K, i6 v- K- ]* t
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point. $ f' s+ W1 B0 L- h) ]) I
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
0 V! B L6 D2 h) V9 z* V4 E ?* _
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 799)
1 e' U8 Y, E0 J- M8 @& ?华为网盘附件：
% ] i$ e( x( g: J【华为网盘】ava.JPG
* L5 ?7 @( m# M7 J" B5 e |
显身卡
